On the safety of Bacillus subtilis and B. amyloliquefaciens: a review.
Novo Nordisk A/S, Bagsvaerd, Denmark.
A S
AS
de Boer
B
B
Diderichsen
D000328:Adult; D000818:Animals; D001407:Bacillus / Q000472:pathogenicity*; D001412:Bacillus subtilis / Q000472:pathogenicity; D002648:Child; D004274:DNA, Recombinant; D004340:Drug Contamination; D005517:Foodborne Diseases / Q000453:epidemiology / Q000382:microbiology; D005818:Genetic Engineering; D016908:Gram-Positive Bacterial Infections / Q000150:complications / Q000453:epidemiology / Q000382:microbiology*; D003932:Heroin; D006801:Humans; D016867:Immunocompromised Host; D007218:Industrial Microbiology; D007223:Infant; D051379:Mice; D009369:Neoplasms / Q000150:complications; D009894:Opportunistic Infections / Q000150:complications / Q000453:epidemiology / Q000382:microbiology*; D012189:Retrospective Studies; D012449:Safety; D015819:Substance Abuse, Intravenous / Q000150:complications; D014774:Virulence
D004274:DNA, Recombinant; D003932:Heroin